生物标志物
生物标志物发现
治疗药物监测
注意事项
医学
药代动力学
计算机科学
生物信息学
生物医学工程
计算生物学
药理学
蛋白质组学
化学
病理
生物
基因
生物化学
作者
Yifan Duan,Jiahui Jin,Shenqi Yang,Xinyi Fan,Yunting Du,Xiaojing Tong,Yonghui Feng,Ji Shi,Xuemei Zhang,Yang Zheng,Yongmin Li,Yang Zhang,Peng Wei
出处
期刊:ACS Sensors
[American Chemical Society]
日期:2025-07-29
卷期号:10 (8): 6010-6019
标识
DOI:10.1021/acssensors.5c01492
摘要
Precision chemotherapy management requires efficient and ultrasensitive dynamic monitoring of drug pharmacokinetics alongside real-time tracking of critical biomarker responses, yet existing clinical diagnostic systems neither achieve real-time integration of these critical parameters nor provide point-of-care testing (POCT) capabilities within a unified analytical framework. Here, we develop a plasmonic fiber-optic sensing platform based on tilted fiber Bragg grating surface plasmon resonance (TFBG-SPR) for point-of-care pharmacokinetic monitoring of platinum chemotherapeutics. By utilizing programmable DNA-based biosensors, our system achieves femtomolar-level detection limits for platinum drugs in minimal sample volumes (10 μL, 100-fold dilution). The platform's modular design enables rapid adaptation to diverse molecular targets with ultratrace multichannel spectral detection, providing inherent capability for parallelized multiomics monitoring by simultaneously addressing chemotherapeutics, DNA, RNA, and protein targets. In a longitudinal clinical cohort study via our proposed sensing platform, we observed an inverse correlation between platinum drug concentrations and miRNA-21 expression levels in colorectal cancer patients undergoing dose-adjusted chemotherapy, while ovarian cancer patients exhibited dynamic miRNA-21 responses to platinum drug concentration variations. These findings highlight the potential utility of miRNA-21 as a candidate biomarker for further investigation into drug efficacy and tumor progression mechanisms. By integrating ultratrace drug monitoring with targeted multiomics profiling on a unified platform─a critical prerequisite for data standardization in future artificial intelligence-driven analysis, our platform bridges the gap between clinical pharmacokinetics and molecular biomarker analysis, offering a fundamental POCT tool for precision chemotherapy optimization and personalized cancer management.
科研通智能强力驱动
Strongly Powered by AbleSci AI